DOC: HEPATITIS B IMMUNE GLOBULIN (HUMAN)


Hepatitis B Immune Globulin (Human) — HyperHEPB® S/D treated with solvent/detergent is a colorless to pale yellow or pink sterile solution of hepatitis B hyperimmune immune globulin for intramuscular administration; it is preservative-free and latex-fre... Document/File: .pdf, filesize: n/a. Filetype: pdf. Filename: hepatitis-b-immune-globulin-human. Title: Hepatitis B Immune Globulin (Human). 2014.

 

File Info:

  • Filesize: N/A
  • Source: fffenterprises_dot_com
  •   Date Archived: 2017-05-27
  •   Author: N/A
 
 
 
 
 

Related Files:

 

  HEPATITIS B IMMUNE GLOBULIN

... PREVENTS HEPATITIS B INFECTION INPATIENTS WHO ARE KNOWN TO HAVE BEEN EXPOSED, INCLUDING NEONATES BORN TO HBSAG-POSITIVE WOMEN, BY PROVIDING PASSIVE IMMUNITY. ACTION AN IMMUNE GAMMA-GLOBULIN FRACTION CONTAINING HIGH TITERS OF ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN. CONFERS PASSIVE IMMUNITY TO HEPATITIS B INFECTION. THERAPEUTIC EFFECTS: PREVENTION OF HEPATITIS B INFECTION. ...
  hepatitis-b-immune-globulin     PDF     2017-05-27  
 

 

  TETANUS IMMUNE GLOBULIN (HUMAN)

... TETANUS IMMUNE GLOBULIN (HUMAN) — HYPERTET® S/D TREATED WITH SOLVENT/DETERGENT IS A COLORLESS TO PALE YELLOW OR PINK STERILE SOLUTION OF TETANUS HYPERIMMUNE IMMUNE GLOBULIN FOR INTRAMUSCULAR ADMINISTRATION; IT IS PRESERVATIVE-FREE, IN A LATEX-FREE DELIVERY SYSTEM. HYPERTET S/D IS PREPARED BY COLD ETHANOL FRACTIONATION FROM THE PLASMA OF DONORS IMMUNIZED WITH TETANUS TOXOID. ...
  tetanus-immune-globulin-human     PDF     2017-05-27  
 

 

  MEASLES IMMUNE GLOBULIN (IG)

... THE FOLLO WING PATIENT GROUPS ARE AT RISK FOR SEVERE DISEASE AND COMPLICATION S FROM MEASLES AND SHOULD RECEIVE IMMUNE G LOBULIN (IG): O INFANTS LESS THAN 12 MONTHS OF AGE O PREGNANT WOMEN WITHOUT EVIDENCE OF MEASLES IMMUNITY O IMMUNOCOMPROMISED PERSONS ...
  measles-immune-globulin-ig     PDF     2017-05-27  
 

 

  EPIDEMIOLOGY AND PREVENTION OF HEPATITIS B VIRUS INFECTION

... HEPATITIS B IS ONE OF THE MOST COMMON INFECTIOUS DISEASES GLOBALLY. IT HAS BEEN ESTIMATED THAT THERE ARE 350 MILLION CHRONIC HEPATITIS B VIRUS (HBV) CARRIERS WORLDWIDE. THE PREVALENCE OF CHRONIC HBV INFECTION VARIES GEOGRAPHICALLY, FROM HIGH (>8%), INTERMEDIATE (2-7%) TO LOW (<2%) PREVALENCE. ...
  epidemiology-and-prevention-of-hepatitis-b-virus-infection     PDF     2017-05-28  
 

 

  IMMUNE GLOBULIN (IVIG AND SCIG)

... THIS DRUG POLICY PROVIDES ASSISTANCE IN INTERPRETING UNITED HEALTHCARE BENEFIT PLANS. WHEN DECIDING COVERAGE, THE MEMBER SPECIFIC BENEFIT PLAN DOCUMENT MUST BE REFERENCED. THE TERMS OF THE MEMBER SPECIFIC BENEFIT PLAN DOCUMENT [E.G., CERTIFICATE OF COVERAGE (COC), SCHEDULE OF BENEFITS (SOB), AND/OR SUMMARY PLAN DESCRIPTION (SPD)] MAY DIFFER GREATLY FROM THE STANDARD BENEFIT PLAN UPON WHICH THIS DRUG POLICY IS BASED ...
  immune-globulin-ivig-and-scig     PDF     2017-05-27  
 

 

  HEPATITIS B VIRUS BIOLOGY

... HEPATITIS B VIRUS (HBV) CAUSES TRANSIENT AND CHRONIC INFECTIONS OF THE LIVER. TRANSIENT INFECTIONS MAY PRODUCE SERIOUS ILLNESS, AND APPROXIMATELY 0.5% TERMINATE WITH FATAL, FULMINANT HEPATITIS. CHRONIC INFECTIONS MAY ALSO HAVE SERIOUS CONSEQUENCES: NEARLY 25% TERMINATE IN UNTREATABLE LIVER CANCER (10). WORLDWIDE DEATHS FROM LIVER CANCER CAUSED BY HBV INFECTION PROBABLY EXCEED ONE MILLION PER YEAR (52, 162). ...
  hepatitis-b-virus-biology     PDF     2017-05-28  
 

 

  HEPATITIS B VIRUS: EPIDEMIOLOGY AND TRANSMISSION RISKS

... HEPATITIS B VIRUS (HBV) INFECTION IS A SERIOUS AND COMMON INFECTIOUS DISEASE OF THE LIVER, AFFECTING MILLIONS OF PEOPLE THROUGHOUT THE WORLD. THE INCUBATION PERIOD FOR HBV IS 45-180 DAYS, MOST COMMONLY 60-90 DAYS. ...
  hepatitis-b-virus-epidemiology-and-transmission-risks     PDF     2017-05-28  
 

 

  HEPATITIS B VIRUS REPLICATION AND INTEGRATION

... CHRONIC INFECTION WITH HEPATITIS B VIRUS (HBV) AFFECTS 240 MILLION PEOPLE WORLDWIDE AND MAY CAUSE LIVER DISEASE INCLUDING HEPATOCELLULAR CARCINOMA (HCC). INITIALLY PATIENTS HAVE HIGH LEVELS OF HBV DNA IN THEIR BLOOD, NO LIVER DISEASE AND EXPRESS THE E ANTIGEN (HBEAG). ...
  hepatitis-b-virus-replication-and-integration     PDF     2017-05-28  
 

 

  DACLATASVIR FOR TREATING CHRONIC HEPATITIS C

... DACLATASVIR IS RECOMMENDED AS AN OPTION FOR TREATING CHRONIC HEPATITIS C IN ADULTS, AS SPECIFIED IN TABLE 1, ONLY IF THE COMPAN Y PROVIDES DACLATASVIR AT THE SAME PRICE OR LOWER THAN THAT AGREED WITH THE COMMERCIAL MEDICINES UNIT. ...
  daclatasvir-for-treating-chronic-hepatitis-c     PDF     2017-05-27  
 

 

  CLINICAL GUIDELINES ON THE MANAGEMENT OF HEPATITIS C

... PATIENTS INFECTED WITH HEPATITIS C VIRUS (HCV) SHOULD BE REFERRED TO A CLINICIAN WITH A PARTICULAR INTEREST IN THE INFECTION. PATIENTS MUST HAVE ACCESS TO ADEQUATE COUNSELLING FROM A HEALTH CARER WITH KNOWLEDGE AND EXPERIENCE OF CHRONIC HCV INFECTION. ALL PATIENTS MUST HAVE ACCESS TO THE APPROPRIATE DIAGNOSTIC AND THERAPEUTIC OPTIONS AVAILABLE IN THE MANAGEMENT OF HCV INFECTION. ...
  clinical-guidelines-on-the-management-of-hepatitis-c     PDF     2017-05-27